Basket | Login

 
 
 
 

Science watch

 

Our science watch section reports on the story behind the media-reported “breakthrough” headlines in dementia, by focusing on the original journal study. Reports of other developments in research on care and cure are also included.

19/07/2021 Systematic review & Meta-analysis provides estimates of Young-Onset Dementia highlighting that the condition affects almost 4 million worldwide
08/07/2021 FDA updates the prescribing information for aducanumab, limiting it to people with MCI or mild AD
08/07/2021 New genomic atlas of proteins in the brain, CSF and plasma identifies potential new targets for AD treatment
07/07/2021 Aducanumab and persons with Down Syndrome: what do we do now? NTG publishes Consensus statement on new drug following FDA approval
30/06/2021 Andrew Feigin discusses results from phase 2 Huntington’s disease trial of anti-semaphorin 4D antibody pepinemab (SIGNAL)
30/06/2021 Article on design and rationale of RECage study published in Journal of Alzheimer's Disease
30/06/2021 Article on design and rationale of RECage study published in Journal of Alzheimer's Disease
24/06/2021 Eli Lilly receives US FDA Breakthrough Therapy designation for donanemab in AD
23/06/2021 Eisai and Biogen have been granted US FDA Grants Breakthrough Therapy designation for lecanemab in AD
21/06/2021 Results from the DIAN-TU trial show that gantenerumab reduces key biomarkers in inherited form of Alzheimer’s disease
16/06/2021 The TANGO Phase II study evaluating gosuranemab in AD did not meet its primary efficacy endpoint
15/06/2021 European Alzheimer’s Disease Consortium (EADC) responds to FDA approval of aducanumab
14/06/2021 Results of Phase II ADAMANT trial of AADVac1 for mild Alzheimer's disease published in Nature Aging
08/06/2021 Anavex completes enrolment of its Phase II/III clinical trial in people with Alzheimer’s disease
07/06/2021 FDA approves aducanumab, a first disease-modifying treatment for Alzheimer's disease

 

 

Options